Live Breaking News & Updates on டேவிட் பிரதான

Stay updated with breaking news from டேவிட் பிரதான. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Addiction charity thanks Trainspotting cast for saving hundreds of lives


Addiction charity thanks Trainspotting cast for saving hundreds of lives
Vital services were funded thanks to support from the cast of T2.
04:30, 25 FEB 2021
Trainspotting 2 cast (Image: Getty Images for Sony Pictures)
Get the stories that matter to you sent straight to your inbox with our daily newsletter.Invalid EmailSomething went wrong, please try again later.
Subscribe
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time. ....

Glasgow City , United Kingdom , Danny Boyle , David Bryce , Ewan Mcgregor , Robert Carlyle , Calton Athletic Recovery Group , Calton Athletic , David Main , Athletic Recovery Group , கிளாஸ்கோ நகரம் , ஒன்றுபட்டது கிஂக்டம் , டேனி பாயில் , டேவிட் பரிஸ் , ய்வந் மக்ரெகர் , ராபர்ட் கார்லைல் , கால்டன் தடகள மீட்பு குழு , கால்டன் தடகள , டேவிட் பிரதான , தடகள மீட்பு குழு ,

Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies


Published: Feb 10, 2021
VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/
 Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led by an exclusively healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine (CCRM); along with new investors EcoR1 Capital, a undisclosed leading global investment firm, Casdin Capital, Samsara BioCapital, and Amplitude Ventures. Proceeds from the financing will support the continuing development of Notch s portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company s proprietary Engineered Thymic Niche (ETN) platform. The finan ....

British Columbia , Peter Zandstra , Mary Moynihan , David Chang , University Of Toronto , Enterprises Holdings Ltd , Allogene Therapeutics Inc , Sunnybrook Research Institute , Centre For Commercialization Of Regenerative Medicine , Prnewswire Notch Therapeutics Inc , Allogene Therapeutics , Lumira Ventures , Holdings Ltd , Regenerative Medicine , Casdin Capital , Samsara Biocapital , Engineered Thymic Niche , David Main , Chief Executive Officer , Notch Board , Notch Therapeutics , Toronto Innovation Acceleration Partners , Notch Therapeutics Closes 85 Million Seriesa Financing To Develop Pipeline Of Renewable Stem Cell Derived Cancer Immunotherapies , பிரிட்டிஷ் கொலம்பியா , மேரி மாய்நீஹாந் , டேவிட் சாங் ,